Establishment of diagnosis and treatment system for rare cancers in healthy population

Establishment of diagnosis and treatment system for rare cancers in healthy population - RareScan study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000051584

Enrollment

200

Registered

2023-07-14

Start date

2023-01-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intrahepatic cholangiocarcinoma and small bowel cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Kei inclusion criteria for Intrahepatic Cholangiocarcinoma 1. Elevated serum alkaline phosphatase (ALP) and intrahepatic bile duct dilation or hepatic mass detected on abdominal ultrasonography 2. Serum Carbohydrate Antigen 19-9 above upper limit of normal 3. Intrahepatic bile duct dilation or hepatic mass detected on abdominal ultrasonography Excluding obvious hepatic hemangioma Key inclusion criteria for Small Bowel Cancer 1. Positive fecal occult blood for 2 consecutive years. 2. Positive fecal occult blood and anemia

Exclusion criteria

Exclusion criteria: None.

Design outcomes

Primary

Measure	Time frame
Percentage of intrahepatic cholangiocarcinoma or small bowel cancer diagnosed in screening-positive patients	—

Countries

Japan

Contacts

Public ContactYuichiro Tozuka

Kanagawa Cancer Center Gastroenterology

tozuka.0x00m@kanagawa-pho.jp0455202222

Outcome results